Calling all health economists! The Tufts-CEVR Cost-Effectiveness Analysis Paper of the Year Contest is back! Submit your CEA for a chance to win $500. Deadline: January 31, 2024. Don't miss out!
Learn more & apply: https://t.co/HYFudQGAwu #HEOR#CEA
The final agenda for the 10/26 symposium in Boston, "Celebrating CEA," is now available.
Panelists include: @Basucally, @contirena1, Emond, Garrison, Lakdawalla, Phelps, Weinstein, etc.
Register in person or online:
https://t.co/XaDi6ztmB0 @TuftsCEVR@DukeMargolis@socmdm
We are thrilled to announce that pioneering #CEA researcher Milton C. Weinstein has joined Panel 2 at the 10/26 Tufts-CEVR / Duke Margolis symposium.
Register now!
In person: https://t.co/X09ZYozhFR
Webinar: https://t.co/WsaGPFDEVY
Furthermore, low- and middle-income countries will need to strengthen their regulatory and reimbursement processes to ensure timely access to new medicines for their populations.
@TuftsCEVR
Numerous breakthrough cancer medicines have emerged in recent years, yet availability remains limited outside a few major, high-income markets. Our latest research in @GlobalHealthBMJ revealed growing disparity worldwide 👇🏼
https://t.co/LqHBlBbUSH
For this to work, high-income countries like the US will need to resist the urge to reference prices from other countries, which neither reflects the value of American patients nor incentivize innovation.
We are pleased to announce that @brianreid, a nationally-recognized expert in prescription drug policy and communications, has joined @TuftsCEVR as a Senior Fellow.
More here: https://t.co/FX9nLdwHUg #heor
What is/will be the role of #CEA in public policy? Hear from @sarahkemond, @contirena1, @ProfLouGarrison, Steven Kymes, and @laprosser during Panel 4 at 10/26 Tufts-CEVR / Duke Margolis event.
Register now:
In-Person: https://t.co/X09ZYoyJQj
Webinar: https://t.co/WsaGPFD76q
The latest in cost-effectiveness analyses...
It will be a great discussion at this panel at the upcoming Boston symposium on Oct 26.
Register:
In person: https://t.co/csekiRQidi
Virtual: https://t.co/zZMmoG3pz7
@Basucally@mel_whittington@socmdm@CHEyork
Eager to learn about new #CEA methods from leading scientists? Join Anirban Basu, Darius Lakdawalla, Melanie Whittington, and Beth Woods for Panel 3 at 10/26 Tufts-CEVR / Duke Margolis Symposium.
Register now:
In Person: https://t.co/X09ZYoyJQj
Webinar: https://t.co/WsaGPFD76q
The 2nd panel at 10/26 Tufts-CEVR / Duke Margolis symposium will feature reflections on CEA from three luminaries: @AnkurFactorial, Marthe Gold, and Charles Phelps.
Register now:
In Person: https://t.co/L5gA6C35ch
Webinar: https://t.co/WsaGPFDEVY
Excited to announce speakers for first of 5 panels at 10/26 Tufts-CEVR/Duke Margolis celebration of #CEA in Boston: Scott Cantor, Patty Synnott, and @drmengli. Stay tuned for more!
Register:
In-person: https://t.co/L5gA6C35ch
Webinar: https://t.co/WsaGPFDEVY
@MooreFound#HEOR
Looking forward to speaking Sept 25 in DC on Medicare's coverage with evidence development program at this event @USC Capital Campus.
Co-hosted by @SchaefferCenter @SUBiodesign & @TuftsCEVR
Info here: https://t.co/Qh4hX5529J @CMSGov#Medicare
Join our team!
We're hiring a Post-doc fellow, sponsored by @GSK, to study the economics of vaccination/infectious disease, learn advanced methods in HEOR and decision science.
Apply today! Applicants considered on rolling basis: https://t.co/dhLDldLtmn.
#HEOR#postdoc#hiring
In today’s @Health_Affairs Forefront, CEVR’s @adelealexandr, @jchambers241, and Genentech’s Stacey Kowal argue Medicare drug price negotiations should consider non-clinical benefits to patients/families as part of unmet need.
#IRA#Pharma
https://t.co/Uq2ynHl0Qz